TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology

Japan

TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology

Japan

Time filter

Source Type

Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Himeno T.,Aichi Medical University | Kato Y.,Aichi Medical University | And 9 more authors.
Internal Medicine | Year: 2017

Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events, and its influence on the renal function. Results The patient’s mean glycated hemoglobin level significantly improved from 7.52±1.16% to 6.95± 0.98% (p<0.001). The body weight of the patients was significantly reduced from 78.0±15.3 kg to 75.6±15.1 kg (p<0.001). The estimated visceral fat area was also significantly reduced from 108.4±44.6 cm2 to 94.5± 45.3 cm2 (p<0.001). The waist circumference, blood pressure, serum alanine aminotransferase, γ-glutamyl transpeptidase, and uric acid levels also showed a significant decrease. The urinary albumin/creatinine ratio (U-ACR) was significantly reduced in the patients whose U-ACR levels were 30-300 mg/gCr at the baseline. The mean eGFR significantly decreased in the patients with a pre-treatment eGFR value of ≥90 mL/min/1.73 m2 but remained unchanged in the patients with a pre-treatment value of <90 mL/min/1.73 m2. A total of 13 adverse events were noted, including systemic eruption (n=1), cystitis (n=2), pudendal pruritus (n=2), nausea (n=1), malaise (n=1), a strong hunger sensation and increased food ingestion (n=1), and non-serious hypoglycemia (n=5). Conclusion SGLT2 inhibitors seemed to be useful in the treatment of obese type 2 diabetes mellitus patients. Furthermore, these data suggest that SGLT2 inhibitors may protect the renal function. © 2017 The Japanese Society of Internal Medicine.


Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Kato Y.,Aichi Medical University | Kondo M.,Aichi Medical University | And 8 more authors.
Journal of the Japan Diabetes Society | Year: 2015

This study was conducted to investigate the efficacy and safety of a SGLT2 inhibitor, ipragliflozin, in Japanese patients with type 2 diabetes. Ipragliflozin was administered to a total of 89 out-patients treated with or without other oral hypoglycemic agents, insulin, or GLP-1 receptor agonists for 12 weeks. Significant decreases were observed in the HbA1c value from 7.46 ± 1.12 % to 7.02 ± 0.99 % (p<0.001), body weight from 76.4 ± 14.4 kg to 74.5 ± 14.2 kg (p<0.001), visceral fat mass from 100.4 ± 39.5 cm2 to 93.2 ± 33.7 cm2 (p= 0.011), systolic and diastolic blood pressure, waist circumference and the EGFR. As adverse events of ipragliflozin treatment, whole body eruption, cystitis and vaginal candidiasis in one case and non-severe hypoglycemia in 2 cases were observed. Ipragliflozin is relatively well-tolerated and effective for the treatment of Japanese obese patients with type 2 diabetes.

Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators
Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators